Moderna Inc plans to request clearance for its coronavirus vaccine in the United States and Europe on Monday, after a new analysis showed the vaccine was highly effective in preventing Covid-19, with no serious safety problems. The primary analysis, which included 196 cases, found the vaccine was 94.1 per cent effective, in line with preliminary findings released earlier this month. None of the participants in the trial who’d received the vaccine developed severe Covid-19. All 30 severe cases observed in the study occurred in participants who received placebo shots, according to a company statement. The shares extended their gains to as much as 12 per cent before US markets opened, hitting a record of $142.85. They have risen more than sixfold since the year began. The new results put the Cambridge, Massachusetts-based biotechnology company on track to have one of the first Covid-19 vaccines to be cleared in the US. A similar vaccine from Pfizer and BioNTech was submitted to US regulators earlier this month and is scheduled to be reviewed ahead of Moderna’s shot.
Courtesyg: Google (photo)
